[1] Kant S, Kronbichler A, Geetha D. Principles of Immunosuppression in the Management of Kidney Disease: Core Curriculum 2022. Am J Kidney Dis. 2022;80(3):393-405.
[2] Gauckler P, Shin JI, Alberici F, et al. Rituximab in membranous nephropathy. Kidney Int Rep. 2021;6(4):881-893.
[3] Kronbichler A, Windpessl M, Pieringer H, Jayne DRW. Rituximab for immunologic renal disease: what the nephrologist needs to know. Autoimmun Rev. 2017;16(6):633-643.
[4] Appel AS, Appel GB. An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases. Nat Clin Pract Nephrol. 2009;5(3):132-142.
[5] Alsharhan L, Beck LH Jr. Membranous nephropathy: core curriculum 2021. Am J Kidney Dis. 2021;77(3):440-453.
[6] Thurman JM. Many drugs for many targets: novel treatments for complement-mediated glomerular disease. Nephrol Dial Transplant. 2017;32(suppl 1):i57-i64.
[7] Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9:1299.